Role of advanced glycation end products and insulin resistance in diabetic nephropathy

被引:45
|
作者
Parwani, Kirti [1 ]
Mandal, Palash [1 ]
机构
[1] Charotar Univ Sci & Technol, PD Patel Inst Appl Sci, Dept Biol Sci, Changa 388421, Gujarat, India
关键词
Advanced glycation end products; insulin resistance; receptor for advanced glycation end products; endoplasmic reticulum stress; diabetic nephropathy; ENDOPLASMIC-RETICULUM STRESS; INDUCED PODOCYTE APOPTOSIS; UNFOLDED PROTEIN RESPONSE; OXIDATIVE STRESS; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; URSODEOXYCHOLIC ACID; DOWN-REGULATION; ELEVATED LEVELS; RECEPTOR;
D O I
10.1080/13813455.2020.1797106
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolic syndrome (MetS), i.e. a cluster of physiological and biochemical abnormalities can lead to diabetic nephropathy (DN). Insulin resistance, impaired fasting glucose are the main signs and symptoms of MetS. Excess sugar can induce various substantial structural changes like formation of advanced glycation end products (AGEs). AGEs are formed due to reaction of reducing sugars with amino groups of proteins, lipids and nucleic acids. AGEs when bound to the receptor for advanced glycation end products (RAGE) activate increased production of pro-inflammatory markers like interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-alpha) along with induction of endoplasmic reticulum (ER) stress. Accumulation of AGEs, enhanced reactive oxygen species (ROS) generation and activation of protein kinase C (PKC), are considered to induce glomerular hypertrophy, podocyte apoptosis, therefore contributing to the development and progression of DN. In this review, we decipher different biochemical and physiological factors that link AGEs and DN.
引用
收藏
页码:95 / 107
页数:13
相关论文
共 50 条
  • [1] Role of advanced glycation end products in diabetic nephropathy
    Forbes, JM
    Cooper, ME
    Oldfield, MD
    Thomas, MC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : S254 - S258
  • [2] THE ROLE OF ADVANCED GLYCATION END PRODUCTS IN PATOGENESIS OF DIABETIC NEPHROPATHY
    Gavrilova, Alina O.
    Severina, Anastasia S.
    Shamhalova, Minara S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2021, 24 (05): : 461 - 469
  • [3] Diabetic nephropathy and advanced glycation end products
    Menè, P
    Festuccia, F
    Polci, R
    Pugliese, F
    Cinotti, GA
    ADVANCED GLYCATION END PRODUCTS IN NEPHROLOGY, 2001, 131 : 22 - 32
  • [4] Advanced glycation end products and the pathogenesis of diabetic nephropathy
    Yamagishi, S
    Masayoshi, T
    Makita, Z
    TYPE-2 DIABETIC NEPHROPATHY IN JAPAN: FROM BENCH TO BEDSIDE, 2001, 134 : 30 - 35
  • [5] Advanced glycation end-products in diabetic nephropathy
    Sugiyama, S
    Miyata, T
    Horie, K
    Iida, Y
    Tsuyuki, M
    Tanaka, H
    Maeda, K
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 : 91 - 94
  • [6] Advanced glycation end-products in diabetic nephropathy
    Friedman, EA
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 : 1 - 9
  • [7] Advanced glycation end products and insulin resistance
    Unoki, Hiroyuki
    Yamagishi, Sho-ichi
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 987 - 989
  • [8] Dietary Advanced Glycation End Products: Their Role in the Insulin Resistance of Aging
    Portero-Otin, Manuel
    de la Maza, M. Pia
    Uribarri, Jaime
    CELLS, 2023, 12 (13)
  • [9] Advanced glycation end products, oxidative stress and diabetic nephropathy
    Yamagishi, Sho-ichi
    Matsui, Takanori
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2010, 3 (02) : 101 - 108
  • [10] Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy
    Yamamoto, T
    Ozono, K
    Miyauchi, A
    Kasayama, S
    Kojima, Y
    Shima, M
    Okada, S
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S161 - S164